TNNC1: A Potential Drug Target and Biomarker for Skeletal and Cardiac Disorders

Target Name: TNNC1

NCBI ID: G7134

TNNC1

TNNC1: A Potential Drug Target and Biomarker for Skeletal and Cardiac Disorders

Skeletal and cardiac muscles are critical for maintaining the overall function of the body. They are responsible for providing support and maintaining posture, as well as participating in physical activities such as movement and maintaining blood pressure. When these muscles fail to function properly due to injury, disease, or other conditions, it can lead to a range of symptoms that can impact the quality of life for individuals. The focus of this article is on TNNC1, a protein that has been identified as a potential drug target and biomarker for skeletal and cardiac disorders.

TNNC1 is a protein that is expressed in a variety of tissues, including skeletal muscles, heart, and kidneys. It is a member of the troponin family, which is a group of transmembrane proteins that play a critical role in the regulation of ion and water transport in various tissues. In the context of skeletal muscles, TNNC1 is involved in the regulation of the contraction and relaxation of muscle fibers, as well as the maintenance of muscle cell structure and function.

Studies have suggested that TNNC1 may be a potential drug target for a range of skeletal and cardiac disorders. For example, some research has suggested that inhibiting the activity of TNNC1 could be a way to treat muscle-related conditions such as muscle weakness, muscle pain, and muscle damage. Additionally, TNNC1 has been shown to be involved in the regulation of muscle contractions, which may make it a potential target for drugs that are designed to treat spasticity and other muscle-related conditions.

In addition to its potential as a drug target, TNNC1 has also been identified as a potential biomarker for a range of skeletal and cardiac disorders. The ability of TNNC1 to participate in the regulation of muscle function and structure makes it an attractive candidate for use as a diagnostic tool for muscle-related conditions. For example, studies have suggested that TNNC1 levels may be elevated in individuals with certain muscle-related conditions, such as muscle dystrophy and myopathies. Additionally, the regulation of TNNC1 activity has been shown to be involved in the pathogenesis of a range of skeletal and cardiac disorders, including muscle-related diseases.

The identification of TNNC1 as a potential drug target and biomarker for skeletal and cardiac disorders has implications for the development of new treatments for a range of conditions. While further research is needed to fully understand the role of TNNC1 in these conditions, the potential for targeting this protein with small molecules or other therapeutic agents is a promising area of research. As such, the development of compounds that can inhibit the activity of TNNC1 and improve muscle function and structure could lead to a range of benefits for individuals with skeletal and cardiac disorders.

Protein Name: Troponin C1, Slow Skeletal And Cardiac Type

Functions: Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments

The "TNNC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNNC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets